PDSB News and Press, PDS Biotechnology Corporation From 03/13/24

Preclinical research published in Vaccines demonstrates Infectimune ® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to vaccine adjuvants Patent for composition of matter and use of Infectimune ® based...

2024-02-16 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

USA News Group – Rates of cancer of the colorectal and anal regions have been on the rise for years in young adults, according to surgeons at Yale Medicine . As well, there are now alarming reports around the world of rising diagnoses of HIV, which is being linked to higher ana...

2024-01-26 18:59:32 ET Summary Preliminary efficacy results from phase 1/2 Mayo Clinic study, using PDS0101 + KEYTRUDA to treat patients with Oropharyngeal cancer, expected in Q2 2024. The global oral cancer treatment market is expected to reach $2.74 billion by 2030. It is sa...

2024-01-23 02:06:02 ET More on PDS Biotechnology PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript PDS Biotechnology: PDS0101 Being Put To The Test PDS Biot...

PRINCETON, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines bas...

PRINCETON, N.J., Jan. 16, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or “the Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines bas...

2024-01-12 19:28:37 ET Summary PDS Biotech is a clinical-stage company focused on developing immunotherapy-based approaches for cancer, with a focus on virus-driven tumors. Their main pipeline project is PDS0101, an immunotherapy targeting the p16 protein found in HPV16-infected c...

2023-11-28 08:11:55 ET More on PDS Biotechnology PDS Biotechnology Corporation (PDSB) Q3 2023 Earnings Call Transcript PDS Biotechnology: PDS0101 Being Put To The Test PDS Biotechnology GAAP EPS of -$0.35 beats by $0.10 PDS Biotech reports encouraging surviva...

PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines bas...